277 related articles for article (PubMed ID: 37355779)
1. Hypertension in chronic kidney disease-treatment standard 2023.
Georgianos PI; Agarwal R
Nephrol Dial Transplant; 2023 Nov; 38(12):2694-2703. PubMed ID: 37355779
[TBL] [Abstract][Full Text] [Related]
2. Management of hypertension in advanced kidney disease.
Georgianos PI; Agarwal R
Curr Opin Nephrol Hypertens; 2022 Jul; 31(4):374-379. PubMed ID: 35727171
[TBL] [Abstract][Full Text] [Related]
3. Predictors of hyperkalemia risk after hypertension control with aldosterone blockade according to the presence or absence of chronic kidney disease.
Gwoo S; Kim YN; Shin HS; Jung YS; Rim H
Nephron Clin Pract; 2014; 128(3-4):381-6. PubMed ID: 25572273
[TBL] [Abstract][Full Text] [Related]
4. Effects of Spironolactone and Chlorthalidone on Cardiovascular Structure and Function in Chronic Kidney Disease: A Randomized, Open-Label Trial.
Edwards NC; Price AM; Mehta S; Hiemstra TF; Kaur A; Greasley PJ; Webb DJ; Dhaun N; MacIntyre IM; Farrah T; Melville V; Herrey AS; Slinn G; Wale R; Ives N; Wheeler DC; Wilkinson I; Steeds RP; Ferro CJ; Townend JN
Clin J Am Soc Nephrol; 2021 Oct; 16(10):1491-1501. PubMed ID: 34462286
[TBL] [Abstract][Full Text] [Related]
5. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade.
Khosla N; Kalaitzidis R; Bakris GL
Am J Nephrol; 2009; 30(5):418-24. PubMed ID: 19738369
[TBL] [Abstract][Full Text] [Related]
6. Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease.
Pisoni R; Acelajado MC; Cartmill FR; Dudenbostel T; Dell'Italia LJ; Cofield SS; Oparil S; Calhoun DA
J Hum Hypertens; 2012 Aug; 26(8):502-6. PubMed ID: 21677673
[TBL] [Abstract][Full Text] [Related]
7. Patiromer to Enable Spironolactone Use in the Treatment of Patients with Resistant Hypertension and Chronic Kidney Disease: Rationale and Design of the AMBER Study.
Agarwal R; Rossignol P; Garza D; Mayo MR; Warren S; Arthur S; Romero A; White WB; Williams B
Am J Nephrol; 2018; 48(3):172-180. PubMed ID: 30176673
[TBL] [Abstract][Full Text] [Related]
8. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease.
Chung EY; Ruospo M; Natale P; Bolignano D; Navaneethan SD; Palmer SC; Strippoli GF
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD007004. PubMed ID: 33107592
[TBL] [Abstract][Full Text] [Related]
9. Low-dose aldosterone blockade as a new treatment paradigm for controlling resistant hypertension.
Calhoun DA
J Clin Hypertens (Greenwich); 2007 Jan; 9(1 Suppl 1):19-24. PubMed ID: 17215651
[TBL] [Abstract][Full Text] [Related]
10. Aldosterone blockers (mineralocorticoid receptor antagonism) and potassium-sparing diuretics.
Epstein M; Calhoun DA
J Clin Hypertens (Greenwich); 2011 Sep; 13(9):644-8. PubMed ID: 21896143
[TBL] [Abstract][Full Text] [Related]
11. Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review.
Mavrakanas TA; Gariani K; Martin PY
Eur J Intern Med; 2014 Feb; 25(2):173-6. PubMed ID: 24315413
[TBL] [Abstract][Full Text] [Related]
12. Mineralocorticoid Receptor Antagonists for Hypertension Management in Advanced Chronic Kidney Disease: BLOCK-CKD Trial.
Bakris G; Yang YF; Pitt B
Hypertension; 2020 Jul; 76(1):144-149. PubMed ID: 32520623
[TBL] [Abstract][Full Text] [Related]
13. Trends in Antihypertensive Medication Use Among US Patients With Resistant Hypertension, 2008 to 2014.
Hwang AY; Dave C; Smith SM
Hypertension; 2016 Dec; 68(6):1349-1354. PubMed ID: 27777360
[TBL] [Abstract][Full Text] [Related]
14. Design and Baseline Characteristics of the Chlorthalidone in Chronic Kidney Disease (CLICK) Trial.
Agarwal R; Cramer AE; Balmes-Fenwick M; Sinha AD; Ouyang F; Tu W
Am J Nephrol; 2020; 51(7):542-552. PubMed ID: 32663820
[TBL] [Abstract][Full Text] [Related]
15. Treatment of Resistant and Refractory Hypertension.
Acelajado MC; Hughes ZH; Oparil S; Calhoun DA
Circ Res; 2019 Mar; 124(7):1061-1070. PubMed ID: 30920924
[TBL] [Abstract][Full Text] [Related]
16. Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension - study protocol for a randomized controlled trial.
Cestário EDES; Fernandes LAB; Giollo-Júnior LT; Uyemura JRR; Matarucco CSS; Landim MIP; Cosenso-Martin LN; Tácito LHB; Moreno H; Vilela-Martin JF; Yugar-Toledo JC
Trials; 2018 Feb; 19(1):101. PubMed ID: 29433578
[TBL] [Abstract][Full Text] [Related]
17. Management of resistant hypertension: aldosterone antagonists or intensification of diuretic therapy?
Verdalles U; García de Vinuesa S; Goicoechea M; Macías N; Santos A; Perez de Jose A; Verde E; Yuste C; Luño J
Nephrology (Carlton); 2015 Aug; 20(8):567-71. PubMed ID: 25818266
[TBL] [Abstract][Full Text] [Related]
18. Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study.
Bianchi S; Bigazzi R; Campese VM
Am J Kidney Dis; 2005 Jul; 46(1):45-51. PubMed ID: 15983956
[TBL] [Abstract][Full Text] [Related]
19. Mineralcorticoid receptor blockers in chronic kidney disease.
Erraez S; López-Mesa M; Gómez-Fernández P
Nefrologia (Engl Ed); 2021; 41(3):258-275. PubMed ID: 36166243
[TBL] [Abstract][Full Text] [Related]
20. Spironolactone and chlorthalidone in uncontrolled elderly hypertensive patients treated with calcium antagonists and angiotensin II receptor-blocker: effects on endothelial function, inflammation, and oxidative stress.
Yamanari H; Nakamura K; Miura D; Yamanari S; Ohe T
Clin Exp Hypertens; 2009 Oct; 31(7):585-94. PubMed ID: 19886856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
